31 January 2017

Facts

Portfolio value Fund commenced Minimum investment Regular Investment Plan (min.) Income distribution date Unit valuation

\$167.24 mn 10 November 2003 A\$20,000 or NZ\$20,000 A\$200 or NZ\$200 per mth/qtr Annual, 30 June

Sydney Business Day

Unit prices App - 2.0365 Red - 2.0263

Performance¹

| | FUND % | MSCI % |
|-------------------------------|--------|--------|
| 1 month | (0.74) | (2.52) |
| 3 months | 6.60 | 3.89 |
| 6 months | 2.42 | (7.35) |
| Calendar year to date | (0.74) | (2.52) |
| 1 year | 7.09 | (3.77) |
| 2 years (compound pa) | 7.00 | 0.75 |
| 3 years (compound pa) | 10.81 | 10.98 |
| 5 years (compound pa) | 19.48 | 21.18 |
| 7 years (compound pa) | 15.62 | 14.16 |
| 10 years (compound pa) | 9.45 | 7.71 |
| Since inception (compound pa) | 8.94 | 8.09 |

Fees

Entry fee Nil Exit fee Nil

Management Expense Ratio/ 1.54% per annum Indirect Cost Ratio (MER/ICR) (inclusive of investment & administration costs)

Brokerage paid

Buy/sell spread 0.25%/0.25%

Performance graph²



Invested positions³

| | LONG % | NET % | CURRENCY % |
|------------------|--------|-------|------------|
| Australia | 4.7 | 4.7 | 16.0 |
| Belgium | 1.8 | 1.8 | |
| Canada | 0.5 | 0.5 | 0.5 |
| Denmark | 2.6 | 2.6 | 2.6 |
| France | 6.2 | 6.2 | |
| Germany | 10.0 | 10.0 | |
| Israel | 1.6 | 1.6 | |
| Italy | 1.5 | 1.5 | |
| Japan | 2.9 | 2.9 | 4.7 |
| Netherlands | 2.0 | 2.0 | |
| Sweden | 2.1 | 2.1 | 2.1 |
| Switzerland | 4.8 | 4.8 | 4.8 |
| United Kingdom | 7.8 | 7.8 | 9.5 |
| United States | 34.2 | 34.2 | 37.2 |
| | 82.8 | 82.8 | |
| Euro Currency | | | 21.5 |
| Norwegian Krone | | | 0.5 |
| Singapore Dollar | | | 0.7 |
| Cash | 17.2 | 17.2 | |
| Total | 100.0 | 100.0 | 100.0 |

Long - 49 stocks

| Top ten positions ⁴ | | | |
|---|---|---|---|
| STOCK | COUNTRY | INDUSTRY | % |
| Sanofi SA AstraZeneca PLC Roche Holding AG Qiagen NV Johnson & Johnson Gilead Sciences Inc H Lundbeck A/S | France UK Switzerland Germany USA USA Denmark | Pharmaceuticals Health Equip & Servs Pharmaceuticals Health Equip & Servs Pharmaceuticals Biotechnology Pharmaceuticals | 3.7 3.6 3.2 2.9 2.7 2.6 2.6 |
| MorphoSys AG Ipsen SA Merus BV | Germany France USA | Biotechnology Pharmaceuticals Biotechnology | 2.5 2.4 2.3 |

| moustry breakdown | | |
|-------------------|--------|-------|
| SECTOR | LONG % | NET % |
| Health Care | 82.8 | 82.8 |

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management ("Platinum") is the responsible entity and issuer of units in the Platinum International Health Care Fund (the "Fund"). The Platinum Trust Product Disclosure Statement No. 10 ("PDS") provides details about the Fund. You can obtain a copy of the PDS from Platinum's website www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), or 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via invest@platinum.com.au. DISCLAIMERS: The information presented in the Fact Sheet is general information only and not intended to be financial product advice. It has not been prepared taking into account any particular investor's or class of investors' investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. You should read the entire PDS and consider your particular investment objectives, financial situation and needs prior to making any investment decision to invest (or divest) in the Fund. You should also obtain professional advice prior to making an investment decision. Some numerical figures in this Fact Sheet have been subject to rounding adjustments

No company or the directors in the Platinum Group® quarantee the performance of the Fund, the repayment of capital, or the payment of income. To the extent permitted by law, no liability is accepted by any company of the Platinum Group or their directors for any loss or damage as a result of any reliance on this information.

4. Top Ten positions shows the Fund's top long share exposure positions as a % of NAV. Long derivative exposures are included, however, short derivative exposures are not.

All data where MSCI is referenced is the property of MSCI. No use or distribution of this data is permitted without the written consent of MSCI. This data is provided "as is" without any warranties by MSCI. MSCI assumes no liability for or in connection with this data. Please see full MSCI disclaimer in www.platinum.com.au/our-funds/platinum-international-he

^{1.} Investment returns are calculated using the Fund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. Investment returns are calculated relative to the MSCI All Country World Health Care Net Index in A\$. The investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term). Source: Platinum for fund returns and RIMES Technologies for MSCI returns.

^{2.} The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$ ("Index"). The investment returns are calculated using the Fund's unit price. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual stock selection process and as a result holdings will vary considerably to the make-up of the Index. The Index is provided as a reference only. Source: Platinum for fund returns and RIMES Technologies for MSCI returns.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives as a % of NAV. The "Net %" represents the exposure of physical holdings and both long and short derivatives. The "Currency %" represents the currency exposure for the Fund as a % of NAV, taking into account currency hedging.